^
    1d
    Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=50, Recruiting, Wake Forest University Health Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    2d
    Breathless and Beyond: Anterior Mediastinal Malignant Peripheral Nerve Sheath Tumor as a Rare Neurofibromatosis Type 1 Manifestation. (PubMed, Clin Case Rep)
    Multidisciplinary evaluation, including biopsy and imaging, is essential for diagnosis, with surgical resection as the primary treatment. Early recognition and vigilant monitoring in NF1 patients are crucial for prompt intervention and improved outcomes.
    Journal
    |
    NF1 (Neurofibromin 1)
    2d
    Phase I Study of Safety and Feasibility of Transarterial Embolization of Incurable Hypervascular Pediatric Soft Tissue Sarcomas (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, University of Alabama at Birmingham | N=10 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    2d
    BAL Fluid Biomarkers in Sarcoma (clinicaltrials.gov)
    P2, N=70, Recruiting, University Health Network, Toronto | Not yet recruiting --> Recruiting
    Enrollment open
    3d
    A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • pazopanib • Yondelis (trabectedin)
    3d
    Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Balversa (erdafitinib)
    3d
    ARST1321: Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery (clinicaltrials.gov)
    P2/3, N=140, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    doxorubicin hydrochloride • pazopanib • cyclophosphamide • ifosfamide • daunorubicin
    3d
    Novel EPS15::KLF17 and EPS15L1::KLF17 Fusions Define a Distinctive Group of MUC4-Positive Spindled to Epithelioid Sarcomas. (PubMed, Am J Surg Pathol)
    EPS15/EPS15L1::KLF17-rearranged sarcoma has distinctive histologic findings, including diffuse MUC4 expression. Recognition is clinically important given its potential for late recurrence and metastasis.
    Journal
    |
    EWSR1 (EWS RNA Binding Protein 1) • CD24 (CD24 Molecule) • MUC4 (Mucin 4, Cell Surface Associated)
    4d
    A Rapidly Growing Cervical Tumor in an Infant: Sarcoma with BCOR Gene Alterations. (PubMed, Int J Surg Pathol)
    At six-month follow-up, the patient remained clinically stable, with no evidence of local recurrence or distant metastasis. This patient's presentation underscores the essential role of comprehensive genomic profiling in distinguishing between histologically similar pediatric sarcomas and guiding appropriate, individualized treatment.
    Journal
    |
    BCL6 (B-cell CLL/lymphoma 6) • BCOR (BCL6 Corepressor)
    4d
    Intracerebral Hemorrhage Secondary to Solitary Fibrous Tumor: A Case Report. (PubMed, Cureus)
    Complete resection was feasible and allowed for histological diagnosis.  Given the possibility of delayed recurrence and the unpredictable behavior of these tumors, long-term postoperative surveillance remains essential. This case highlights the importance of considering underlying neoplasms in spontaneous intracerebral hemorrhage and emphasizes the role of timely surgical management in improving diagnostic accuracy and clinical outcomes.
    Journal
    |
    STAT6 (Signal transducer and activator of transcription 6)
    4d
    Phase I Study Compound 451238 and Radiotherapy in Soft-tissue Sarcoma (clinicaltrials.gov)
    P1/2, N=12, Completed, Royal Marsden NHS Foundation Trust | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Compound 451238